Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Broich

Showing results (1-10 of 93) with videos related to

Pageof 10
Sort By:
International Psychogeriatrics|April 17, 2007
Outcome measures in clinical trials on medicinal products for the treatment of dementia: a European regulatory perspectiveKarl Broich
International Psychogeriatrics|September 30, 2005
Regulatory issues in vascular dementia: a European perspectiveKarl Broich
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|March 10, 2009
Committee for Medicinal Products for Human Use (CHMP) assessment on efficacy of antidepressantsKarl Broich,
Der Nervenarzt|September 24, 2025
[Dementia: changes from ICD-10 to ICD-11. German Version]Frank Jessen, Karl Broich
Der Nervenarzt|October 14, 2025
Dementia: changes from ICD-10 to ICD-11Frank Jessen, Karl Broich
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|May 14, 2013
[Cancer: Is it really so different? Particularities of oncologic drugs from the perspective of the pharmaceutical regulatory agency]Harald Enzmann, Karl Broich
Der Nervenarzt|August 18, 2025
[Digital health applications from a regulatory perspective-Experiences and current developments]Florian Strauch, Karl Broich
Thrombosis and Haemostasis|September 28, 2006
Selective COX-2 inhibitors and risk of thromboembolic events - regulatory aspectsHans-Karl Heim, Karl Broich
European Archives of Psychiatry and Clinical Neuroscience|November 6, 2009
Principle standards and problems regarding proof of efficacy in clinical psychopharmacologyHans-Jürgen Möller, Karl Broich
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz|May 5, 2018
[Erratum to: Antibiotic resistance: Complex challenges require comprehensive solutions.]Lothar H Wieler, Karl Broich
Pageof 10

Showing results (1-10 of 93) with videos related to

Sort By:
Pageof 10
International Psychogeriatrics|April 17, 2007
Outcome measures in clinical trials on medicinal products for the treatment of dementia: a European regulatory perspectiveKarl Broich
International Psychogeriatrics|September 30, 2005
Regulatory issues in vascular dementia: a European perspectiveKarl Broich
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|March 10, 2009
Committee for Medicinal Products for Human Use (CHMP) assessment on efficacy of antidepressantsKarl Broich,
Der Nervenarzt|September 24, 2025
[Dementia: changes from ICD-10 to ICD-11. German Version]Frank Jessen, Karl Broich
Der Nervenarzt|October 14, 2025
Dementia: changes from ICD-10 to ICD-11Frank Jessen, Karl Broich
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|May 14, 2013
[Cancer: Is it really so different? Particularities of oncologic drugs from the perspective of the pharmaceutical regulatory agency]Harald Enzmann, Karl Broich
Der Nervenarzt|August 18, 2025
[Digital health applications from a regulatory perspective-Experiences and current developments]Florian Strauch, Karl Broich
Thrombosis and Haemostasis|September 28, 2006
Selective COX-2 inhibitors and risk of thromboembolic events - regulatory aspectsHans-Karl Heim, Karl Broich
European Archives of Psychiatry and Clinical Neuroscience|November 6, 2009
Principle standards and problems regarding proof of efficacy in clinical psychopharmacologyHans-Jürgen Möller, Karl Broich
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz|May 5, 2018
[Erratum to: Antibiotic resistance: Complex challenges require comprehensive solutions.]Lothar H Wieler, Karl Broich
Pageof 10